跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

O-002

Supelco

羟考酮标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C18H21NO4
CAS号:
76-42-6
分子量:
315.36
EC 号:
200-659-6
MDL编号:
MFCD00190613
UNSPSC代码:
41116107
PubChem化学物质编号:
329818811
NACRES:
NA.24

等级

certified reference material

质量水平

300

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

forensics and toxicology

包装形式

single component solution

储存温度

2-8°C

SMILES字符串

COc1ccc2C[C@H]3N(C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O

InChI

1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1

InChI key

BRUQQQPBMZOVGD-XFKAJCMBSA-N

基因信息

human ... OPRM1(4988)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

该认证的加标溶液®适用于从临床毒理学和尿液药物测试到法医分析的羟考酮GC/MS或LC/MS测试的许多应用。羟考酮是一种半合成阿片类镇痛药，以许多商品名出售，包括OxyContin®和Percocet®，用于治疗中度至重度疼痛。羟考酮还以“Roxies”，“Blues”和“Perks”等街头名称非法出售。

应用


  • 儿科围手术期护理中的羟考酮溶液：研究人员已经研究了羟考酮溶液与采用Y型接头的儿科环境中其它围手术期药物的兼容性，有助于儿童安全有效的疼痛管理方案（Youssef et al., 2024).

  • 羟考酮的分析测试：羟考酮溶液可用于先进分析技术（如底物喷雾质谱法），用于检测唾液中的羟考酮和纳洛酮，展示了其在快速灵敏诊断环境中的应用 (Millán-Santiago et al., 2024).

  • 运动生理学领域中阿片受体激动剂的研究：研究探索了在调节运动生理反应方面阿片受体激动剂（包括羟考酮）与其它化合物的相互作用，表明了其在复杂生理研究中的作用（Anselmi et al., 2024).

  • 疼痛管理的药理学评估：羟考酮溶液可用于防止阿片类药物暴露（opioid exposure）的多价疫苗接种策略，为针对阿片样药物相关疾病治疗干预措施的开发提供见解（Song et al., 2024).

  • 镇痛药的定量分析：通过使用HPLC-DAD和LC-MS/MS方法，羟考酮溶液在同时测定术后溶液中多种镇痛药方面至关重要，突显了其在药代动力学研究和药物监测中的重要性（Yao et al., 2024）。

推荐产品

在我们的NMR在线平台ChemisTwin®上可以找到本品对应的数字化标准物质。您可使用ChemisTwin®上的数字等效品鉴定您的样品并进行定量分析（使用数字化外标）。可查看该物质的NMR谱图，只需点击几次鼠标，就能进行在线样品比对。欢迎点击了解更多，开启免费试用之旅。

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
OxyContin is a registered trademark of Purdue Pharma L.P.
Percocet is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相关产品

产品编号
说明
价格

P-071

13种疼痛管理混标 溶液, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

O-020

五种阿片类混标 溶液, 250 μg/mL each component in methanol, ampule of 1.0 mL, certified reference material, Cerilliant®

N-011

Noroxycodone hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-032

Noroxycodone-D3 hydrochloride solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

O-005

羟考酮-D3标准液 CRM 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-006

羟考酮-D3标准液 CRM 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-007

羟考酮-D6标准液 CRM 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-008

羟考酮-D6标准液 CRM 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-002S

羟考酮标准液 溶液, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes,Central nervous system

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Raymond E Glazier et al.
Disability and health journal, 6(2), 107-115 (2013-03-20)
Substance abuse (SA) is a grave and pervasive social problem associated with severe personal and social costs that affect persons with disabilities disproportionally. Most previous research has found SA prevalence to be greater among persons with disabilities than among those
Reply to commentary.
Stephen F Butler
The journal of pain : official journal of the American Pain Society, 14(4), 361-362 (2013-04-04)
Prescrire international, 22(134), 10-11 (2013-02-02)
At high doses of oxycodone, the fixed-dose combination of oxycodone plus naloxone complicates therapeutic management and will likely have lower analgesic efficacy.
James P Zacny et al.
Experimental and clinical psychopharmacology, 21(2), 103-111 (2013-02-21)
Two prominent and important risk factors for nonmedical use of prescription opioids (NMUPO) identified in epidemiological studies are smoking status and sex (i.e., there is a greater likelihood of NMUPO in smokers and in men, relative to nonsmokers and women).
Dustin B Stephens et al.
Journal of studies on alcohol and drugs, 74(3), 386-395 (2013-03-16)
Alcohol consumption dramatically increases the risk of liver damage among those with hepatitis C virus (HCV) infection, yet the impact of HCV status disclosure and standard informational counseling on alcohol use among rural drug users remains poorly understood. In this
查看所有相关文献

商品

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门